SUN-357 Trial in Progress: A Multicenter, Dose-titration, Open-Label Phase 2b Study of Nevanimibe Hydrochloride, a Novel ACAT1 Inhibitor, for the Treatment of Classic Congenital Adrenal Hyperplasia

More than 90% of classic congenital adrenal hyperplasia (CAH) patients have defects in the cytochrome P450 enzyme steroid 21-hydroxylase, resulting in the inability to produce cortisol as well as the overproduction of androgens and androgen precursors such as 17-hydroxyprogesterone (17-OHP). Managem...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Vivian, Ijzerman, M. Marian, Plaunt, Marianne, Mohideen, Pharis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552740/
http://dx.doi.org/10.1210/js.2019-SUN-357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552740/
http://dx.doi.org/10.1210/js.2019-SUN-357

Ejemplares similares